Published in J Mol Biol on April 24, 2010
Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names. Viruses (2014) 1.33
Filoviral immune evasion mechanisms. Viruses (2011) 1.10
Recognition of virus infection and innate host responses to viral gene therapy vectors. Mol Ther (2010) 1.10
Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol (2015) 1.07
Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J Virol (2010) 1.07
Camouflage and misdirection: the full-on assault of ebola virus disease. Cell (2014) 1.07
Ebolavirus VP35 is a multifunctional virulence factor. Virulence (2010) 1.02
In silico derived small molecules bind the filovirus VP35 protein and inhibit its polymerase cofactor activity. J Mol Biol (2014) 0.96
Development of RNA aptamers targeting Ebola virus VP35. Biochemistry (2013) 0.93
The structure of the C-terminal domain of the Zaire ebolavirus nucleoprotein. Acta Crystallogr D Biol Crystallogr (2014) 0.92
Ebolavirus VP35 coats the backbone of double-stranded RNA for interferon antagonism. J Virol (2013) 0.90
Hiding the evidence: two strategies for innate immune evasion by hemorrhagic fever viruses. Curr Opin Virol (2012) 0.87
Innate immune evasion by filoviruses. Virology (2015) 0.82
Predictive and comparative analysis of Ebolavirus proteins. Cell Cycle (2015) 0.79
Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses. Sci Rep (2016) 0.78
When your cap matters: structural insights into self vs non-self recognition of 5' RNA by immunomodulatory host proteins. Curr Opin Struct Biol (2016) 0.78
Neglected filoviruses. FEMS Microbiol Rev (2016) 0.78
Molecular Mechanisms of Innate Immune Inhibition by Non-Segmented Negative-Sense RNA Viruses. J Mol Biol (2016) 0.76
The host E3-Ubiquitin ligase TRIM6 ubiquitinates the Ebola virus VP35 protein and promotes virus replication. J Virol (2017) 0.75
Crystal Structure of the Marburg Virus VP35 Oligomerization Domain. J Virol (2016) 0.75
Molecular dynamics exploration of the binding mechanism and properties of single-walled carbon nanotube to WT and mutant VP35 FBP region of Ebola virus. J Biol Phys (2017) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR (1995) 93.94
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res (2007) 37.31
Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr (2001) 15.88
Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr D Biol Crystallogr (2006) 14.21
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol (2005) 9.17
Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol Biol (2004) 8.02
Automated refinement of protein models. Acta Crystallogr D Biol Crystallogr (1993) 7.88
wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refined dummy atomic models. Acta Crystallogr D Biol Crystallogr (1997) 5.58
Thermofluor-based high-throughput stability optimization of proteins for structural studies. Anal Biochem (2006) 5.05
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
MDA5/RIG-I and virus recognition. Curr Opin Immunol (2008) 4.05
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Discovery of swine as a host for the Reston ebolavirus. Science (2009) 3.68
Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP. J Virol (2002) 3.62
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol Cell (2002) 2.80
The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog (2007) 2.48
Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol (2005) 2.27
Principles of intracellular viral recognition. Curr Opin Immunol (2006) 2.25
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol (2009) 2.10
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 2.01
The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J Virol (2006) 2.00
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J Virol (2008) 1.96
RIG-I family RNA helicases: cytoplasmic sensor for antiviral innate immunity. Cytokine Growth Factor Rev (2007) 1.94
Marburg and Ebola viruses. Adv Virus Res (1996) 1.81
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol (2010) 1.72
Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A (2009) 1.71
Universal screening methods and applications of ThermoFluor. J Biomol Screen (2006) 1.69
Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol (2008) 1.65
Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology (2005) 1.63
Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J (2006) 1.60
Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med (2004) 1.52
Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc Natl Acad Sci U S A (2009) 1.48
Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol (2009) 1.46
A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology (2005) 1.40
Triggering antiviral response by RIG-I-related RNA helicases. Biochimie (2007) 1.37
Homo-oligomerization of Marburgvirus VP35 is essential for its function in replication and transcription. J Virol (2005) 1.30
Filovirus research: knowledge expands to meet a growing threat. J Infect Dis (2007) 1.19
Regions in Ebola virus VP24 that are important for nucleocapsid formation. J Infect Dis (2007) 1.19
RIG-I and dsRNA-induced IFNbeta activation. PLoS One (2008) 1.12
RIG-I activation inhibits ebolavirus replication. Virology (2009) 1.12
Role of RIG-I, MDA-5, and PKR on the expression of inflammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int Arch Allergy Immunol (2007) 1.12
Outbreak news. Ebola Reston in pigs and humans, Philippines. Wkly Epidemiol Rec (2009) 1.11
Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston). Comp Immunol Microbiol Infect Dis (2007) 1.02
A filovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J Virol (2008) 1.01
Expression, purification, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.90
Ebola Reston virus detected pigs in the Philippines. Euro Surveill (2009) 0.79
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J Virol (2006) 3.50
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep (2008) 2.65
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS One (2008) 2.45
Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. PLoS Pathog (2006) 2.26
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2002) 2.21
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Rapid detection protocol for filoviruses. J Clin Virol (2004) 2.13
Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol (2009) 2.10
Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol (2010) 2.01
Nipah virus V and W proteins have a common STAT1-binding domain yet inhibit STAT1 activation from the cytoplasmic and nuclear compartments, respectively. J Virol (2004) 1.98
Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J Virol (2007) 1.97
Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe (2013) 1.97
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol (2009) 1.94
Internal dynamics control activation and activity of the autoinhibited Vav DH domain. Nat Struct Mol Biol (2008) 1.93
Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res (2009) 1.91
A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol (2011) 1.85
Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. J Virol (2002) 1.81
DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog (2012) 1.80
Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol (2006) 1.73
Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J Virol (2010) 1.72
A viral RNA structural element alters host recognition of nonself RNA. Science (2014) 1.71
Structure of the Ebola VP35 interferon inhibitory domain. Proc Natl Acad Sci U S A (2009) 1.71
Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J Virol (2002) 1.71
Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. J Virol (2005) 1.69
Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. J Immunol (2011) 1.68
Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog (2010) 1.63
Effects of influenza A virus NS1 protein on protein expression: the NS1 protein enhances translation and is not required for shutoff of host protein synthesis. J Virol (2002) 1.63
VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob Agents Chemother (2006) 1.63
Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology (2005) 1.63
Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol (2012) 1.59
Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization. J Virol (2006) 1.52
Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell (2010) 1.51
Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol (2009) 1.50
Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol (2009) 1.50
Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med (2013) 1.49
Phosphorylation of VP30 impairs ebola virus transcription. J Biol Chem (2002) 1.47
Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J Virol (2009) 1.46
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis (2012) 1.41
A reconstituted replication and transcription system for Ebola virus Reston and comparison with Ebola virus Zaire. Virology (2005) 1.40
The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol (2004) 1.39
Capsid protein of eastern equine encephalitis virus inhibits host cell gene expression. J Virol (2007) 1.35
Forty-five years of Marburg virus research. Viruses (2012) 1.34
Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J Virol (2009) 1.31
Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat Commun (2010) 1.29
Inclusion bodies are a site of ebolavirus replication. J Virol (2012) 1.29
Ebola virus transcription activator VP30 is a zinc-binding protein. J Virol (2003) 1.29
Discussions and decisions of the 2012–2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012–June 2013. Arch Virol (2014) 1.27
Oligomerization of Ebola virus VP30 is essential for viral transcription and can be inhibited by a synthetic peptide. J Biol Chem (2003) 1.24
Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. J Virol (2012) 1.20
Deep sequencing identifies noncanonical editing of Ebola and Marburg virus RNAs in infected cells. MBio (2014) 1.20
Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog (2012) 1.19
Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology (2007) 1.19
Nipah virus sequesters inactive STAT1 in the nucleus via a P gene-encoded mechanism. J Virol (2009) 1.18
Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A (2012) 1.18
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition. Cell Microbiol (2009) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Rescue of recombinant Marburg virus from cDNA is dependent on nucleocapsid protein VP30. J Virol (2006) 1.15
The Ebola virus genomic replication promoter is bipartite and follows the rule of six. J Virol (2005) 1.14
Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol (2011) 1.14
Neutralizing anti-influenza virus monoclonal antibodies: therapeutics and tools for discovery. Int Rev Immunol (2009) 1.13
An upstream open reading frame modulates ebola virus polymerase translation and virus replication. PLoS Pathog (2013) 1.12
Chimeric influenza A viruses with a functional influenza B virus neuraminidase or hemagglutinin. J Virol (2003) 1.12
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions. Antimicrob Agents Chemother (2011) 1.11
Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J Virol (2011) 1.10
Filoviral immune evasion mechanisms. Viruses (2011) 1.10
Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch Virol (2013) 1.10
Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J Virol (2010) 1.07